Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bazinet Alexandre, Bataller Alex, Chien Kelly, Sasaki Koji, Montalban-Bravo Guillermo, Hammond Danielle, Bouligny Ian, Swaminathan Mahesh, Jen Wei Ying, Kugler Eitan, Kanagal-Shamanna Rashmi, Kadia Tapan, Borthakur Gautam, DiNardo Courtney, Short Nicholas, Pemmaraju Naveen, Jabbour Elias, Daver Naval, Ravandi Farhad, Urrutia Samuel, Gener-Ricos Georgina, Braish Julie, Briski Robert, Rodriguez-Sevilla Juan Jose, Li Ziyi, Champlin Richard E, Shpall Elizabeth J, Alousi Amin, Oran Betul, Hosing Chitra, Ramdial Jeremy L, Olson Amanda, Pierce Sherry, Chen Julianne, Kantarjian Hagop, Garcia-Manero Guillermo, Popat Uday
Аннотация
Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified 2045 patients with HR-MDS, of which 427 (21%) underwent SCT. The median post-SCT overall survival (OS) was 23.9 months, progression-free survival (PFS) was 14.4 months, 5-year cumulative incidence (CI) of relapse was 37%, and 5-year CI of treatment-related mortality (TRM) was 25%. There were no significant differences in OS, PFS, CI of relapse, or CI of TRM between age categories. Survival improved over the observation period (median 11.8 months in 2000-2010, 28.2 months in 2011-2016, and 40.2 months in 2017-2023; p = 0.01). By multivariate analysis, TP53 status was the most important predictor of post-SCT OS. Patients with TP53-wild type MDS had an OS of 69% at 5 years (HR for death 0.32 with SCT, p < 0.001). Patients with TP53 mutations had poor outcomes, with OS of 9.1 months in monoallelic (HR for death 0.88 with SCT, p = 0.69) and 6.8 months in biallelic (HR for death 0.76 with SCT, p = 0.14). SCT can lead to excellent long-term survival in TP53-wild type HR MDS.